Dipraglurant Immediate Release (IR) Formulation for the Treatment of Parkinson’s disease Levodopa Induced Dyskinesia (PD-LID)
نویسنده
چکیده
The combined peak U.S. annual sales potential (excluding disease modification) for the PD indications alone is estimated to be in the range of $1.8bn to $2.7bn , (source Michael J Fox Foundation 2011). Datamonitor market research with PD specialists in the U.S., EU, China and India show that dipraglurant has an attractive product profile and can capture over $1 billion in annual revenues if fully exploited in PD indications. Additional labelling for indications in non-parkinsonian movement disorders such as dystonias, offers similar peak sales potential.
منابع مشابه
Dissimilar mechanistic background of peripheral and orofacial hyperkinesia in patients with Parkinson’s disease and levodopa-induced dyskinesia
Introduction: Long-term levodopa treatment of Parkinson’s disease (PD) is frequently complicated by spontaneously occurring involuntary muscle movements called dyskinesia. The exact pathological mechanism of this complication has not yet been elucidated. We have previously demonstrated that in PD patients the vulnerability to develop peripheral but not orofacial dyskinesia is associated w...
متن کاملDiabetes Increases the Incidence of Levodopa-Induced Dyskinesia in Parkinson’s Disease; A Case-Control Study
Background and Objective: Dyskinesia is a debilitating complication of Parkinsonchr('39')s disease (PD), which appears due to some known risk factors. The effect of diabetes and high plasma glucose on the manifestation of dyskinesia has been evaluated in just a few previous reports. The current study aimed to assess the mentioned correlation. Materials and Methods: In this case-control study, ...
متن کاملOnce-daily pramipexole for the treatment of early and advanced idiopathic Parkinson’s disease: implications for patients
Immediate-release (IR) pramipexole is indicated for the symptomatic treatment of idiopathic Parkinson's disease (PD), either alone (without levodopa) or in combination with levodopa, that is, during the entire progress of disease up to the advanced stage. It is also currently indicated for the treatment of moderate-to-severe primary restless legs syndrome (RLS). An extended-release (ER) formula...
متن کاملDifferent Dyskinesias in Parkinson’s Disease and Their Relationship to Levodopa
Levodopa is the principal agent in the treatment of Parkinson’s disease (PD). Unfortunately the therapeutic benefits are optimal only in the early stages of the disease, with long-term use associated with motor complications such as levodopa-induced dyskinesia (LID). Risk factors associated with the development of LID are generally accepted to involve the degree of dopamine (DA) denervation in ...
متن کاملPopulation Pharmacodynamics of IPX066: An Oral Extended-Release Capsule Formulation of Carbidopa–Levodopa, and Immediate-Release Carbidopa–Levodopa in Patients With Advanced Parkinson’s Disease
A pharmacodynamic model is presented to describe the motor effects (tapping rate, Unified Parkinson's Disease Rating Scale [UPDRS] Part III, and investigator-rating of ON/OFF, including dyskinesia) of levodopa (LD) in patients with advanced idiopathic Parkinson's disease (PD) treated with immediate-release (IR) carbidopa-levodopa (CD-LD) or an extended-release (ER) formulation of CD-LD (IPX066)...
متن کامل